Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Genichiro, Nakajima, Shogo, Watashi, Koichi, Torii, Shiho, Suzuki, Rigel, Fukuhara, Takasuke, Ohoka, Nobumichi, Inoue, Takao, Demizu, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014634/
https://www.ncbi.nlm.nih.gov/pubmed/35641031
http://dx.doi.org/10.1016/j.jphs.2022.04.001
Descripción
Sumario:Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.

Ejemplares similares